A股異動 | 獲券商看好 譜尼測試(300887.SZ)漲7.8%創新高
格隆匯5月31日丨譜尼測試(300887.SZ)股價高位震盪,盤中最高見72.45元創新高,現報72.28元,漲幅7.88%,最新總市值98.88億,換手率6.7%,年內累計漲幅超60%。華泰證券指,5月25日譜尼測試公吿,上海子公司成為特斯拉供應商,鞏固新能源車測試領域地位。新領域拓展卓有成效,醫學與消費品發力,有望成為21年重要收入增量。傳統領域鞏固優勢地位,食品與環境需求恢復。公司持續優化銷售與管理機制,着力提升人均產值。上調盈利預測,預計21-23年EPS為1.61/2.13/2.78元,目標PE48x,目標價77.28元,維持“增持”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.